SIRT1 and type 2 diabetes mellitus: Because anti-inflammatory and cell-protective mechanisms mediated by SIRT1 are suppressed in diabetes, small SIRT1 activators are considered to be potential drugs for the treatment of T2DM, obesity, and MetS, among other disorders [175].